Market Herald logo


Be the first with the news that moves the market
  • CloudMD (DOC) receives U.S. patent approval for its proprietary Real Time Intervention Platform
  • This platform is the technology that supports interoperability and provides the integration of all of CloudMD’s healthcare capabilities
  • Platform is trusted by various local, state and federal agencies including the
    U.S. Department of Justice and U.S Department of Health and Human Services
  • RTIP will power its data warehouse to support real time analytics, data and outcomes
  • CloudMD Software & Services Inc. (DOC) is up 2.78 per cent, trading at C$1.48 at 1:15 pm ET

CloudMD Software & Services Inc. (DOC) has received US patent approval for its Real Time Intervention Platform.

The Real Time Intervention Platform is the technology backbone for CloudMD’s comprehensive healthcare platform that addresses all points of a patient’s care.

Given the continued rapid growth of CloudMD, receiving patent approval is very important for CloudMD, as it protects its proprietary intellectual property.

This technology connects and integrates the Company’s capabilities and supports a data exchange across primary care, mental health, specialists, rehabilitation, occupational health, and education, providing a holistic approach to managing the health and wellness of individuals.

CloudMD is targeting the employer market with its comprehensive healthcare platform and has already onboarded over 260,000 individuals who are receiving customized health plans.

A key component of this technology is the ability to report data, analytics and outcomes to measure the success of programs securely with all the required privacy controls.

This connected approach to care is already receiving positive outcomes with a net promoter score of 78 per cent and results where 91 per cent of reassessed individuals with depression showing improvement and 89 per cent of reassessed individuals with anxiety showing symptom improvement.

Dr. Essam Hamza, CEO of CloudMD commented, “Receiving this patent now is both extremely critical and timely as it safeguards our proprietary technology, which is core to our integrated healthcare platform.”

“The RTIP technology connects all our different capabilities and shares valuable data in real-time. We have already seen significant growth across the United States as various modules of our platform are being rolled out to support a number of key health and wellness programs. As a key part of our expansion strategy, we will continue to roll out these programs across North America,” added Hamza.

The RTIP platform’s patent is a testament to its purposeful ability to deliver real-time health data integration in a secure manner.

The platform has been tested and continues to be used by the U.S. Department of Justice, U.S. Department of Health and Human Services as well as by various other government agencies at the federal, state and local levels.

The RTIP platform has multiple use cases within the U.S. including, but not limited to, law enforcement health and wellness, substance use disorder programs and in the realm of opioid addiction.

Within the law enforcement community, the RTIP platform is the foundation of the integrated platform and is being used to provide access to health and wellness resources and support to the law enforcement community. 

Individuals can access the platform and resources from one point within their own private environment without compromising their privacy and data security. This platform is being used widely across various states and counties and currently, 1,500 law enforcement officials have access.

The RTIP platform is also being used to support the national opioid crisis, connecting public health, social services, and public safety systems to address the real-time needs of the individuals who have overdosed or may be at risk. 

The contract covers a six-year period and CloudMD is one of the five companies that has been collaboratively awarded the contract.

CloudMD is transforming the delivery of healthcare using technology and by providing a patient-centric approach, with an emphasis on continuity of care. By leveraging healthcare technology, it is building one, connected platform that addresses all points of a patient’s healthcare journey and provides better access to care and improved outcomes.

CloudMD Software & Services Inc. (DOC) is up 2.78 per cent, trading at C$1.48 at 1:15 pm ET.

More From The Market Herald
LexaGene - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) closes multiple MiQLab sales

LexaGene (LXG) has received purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
The Market Herald Video

" FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.
The Market Herald Video

" Adastra Holdings (CSE:XTRX) reports record third-quarter results

Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020.